Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
/ blood
Breast Neoplasms
/ blood
Carboplatin
Chemokines
/ blood
Cyclophosphamide
Disease-Free Survival
Female
Humans
Interleukin-15
/ blood
Lymphatic Metastasis
Middle Aged
Neoplastic Cells, Circulating
/ pathology
Prognosis
Progression-Free Survival
Survival Analysis
Thiotepa
Breast cancer
Circulating tumor cells
Eotaxin
Interleukin 15
SUCCESS study
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
05
2020
accepted:
05
09
2020
pubmed:
16
9
2020
medline:
23
2
2021
entrez:
15
9
2020
Statut:
ppublish
Résumé
Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for breast cancer patients. Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 patients' sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera for Interleukin 15 (IL-15) and eotaxin. Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly correlate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS and DFS, showed statistically significant elevated eotaxin values. These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies.
Sections du résumé
BACKGROUND
Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for breast cancer patients.
METHODS
Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 patients' sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera for Interleukin 15 (IL-15) and eotaxin.
RESULTS
Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly correlate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS and DFS, showed statistically significant elevated eotaxin values.
CONCLUSION
These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies.
Identifiants
pubmed: 32929618
doi: 10.1007/s00404-020-05793-y
pii: 10.1007/s00404-020-05793-y
pmc: PMC7854415
doi:
Substances chimiques
Biomarkers, Tumor
0
Chemokines
0
Interleukin-15
0
Cyclophosphamide
8N3DW7272P
Thiotepa
905Z5W3GKH
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-230Investigateurs
Theresa Vilsmaier
(T)
Helene Hildegard Heidegger
(HH)
Lennard Schröder
(L)
Références
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Science. 1994 May 13;264(5161):965-8
pubmed: 8178155
J Clin Oncol. 2007 Oct 20;25(30):4813-20
pubmed: 17947730
FASEB J. 1999 Sep;13(12):1575-85
pubmed: 10463949
Clin Exp Immunol. 2011 Feb;163(2):165-77
pubmed: 21087443
Nature. 2007 Sep 27;449(7161):419-26
pubmed: 17898760
Int J Mol Med. 2016 Sep;38(3):679-86
pubmed: 27460304
Biochem Biophys Res Commun. 1997 Mar 27;232(3):754-8
pubmed: 9126349
J Exp Clin Cancer Res. 2006 Dec;25(4):529-36
pubmed: 17310844
Cell. 2007 Apr 6;129(1):33-6
pubmed: 17418783
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Br J Haematol. 2002 Nov;119(2):467-74
pubmed: 12406087
Mol Immunol. 2005 Feb;42(4):547-55
pubmed: 15607812
J Immunol. 2007 Apr 1;178(7):4222-9
pubmed: 17371978
Curr Opin Pharmacol. 2004 Aug;4(4):392-7
pubmed: 15251134
J Exp Med. 1994 Oct 1;180(4):1395-403
pubmed: 7523571
J Exp Med. 2004 Mar 1;199(5):725-30
pubmed: 14993255
Cancer Res. 2002 Aug 1;62(15):4390-7
pubmed: 12154045
Br J Dermatol. 2001 May;144(5):1016-23
pubmed: 11359391
J Pathol. 2000 Jun;191(2):193-201
pubmed: 10861581
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
pubmed: 9747868
Nat Immun. 1993 Jul-Oct;12(4-5):279-92
pubmed: 8257832
Nat Immunol. 2007 Aug;8(8):856-63
pubmed: 17618288
Science. 1994 Nov 11;266(5187):1045-7
pubmed: 7973659
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
pubmed: 16288118
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Lung Cancer. 2002 Jan;35(1):23-8
pubmed: 11750709
Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83
pubmed: 11900992
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24
pubmed: 16857794
J Immunol. 1998 Feb 15;160(4):1666-76
pubmed: 9469423
Psychooncology. 2014 Mar;23(3):339-45
pubmed: 24136882
World J Surg Oncol. 2013 Aug 27;11:213
pubmed: 23981902
Cancer Lett. 2017 Mar 28;389:49-58
pubmed: 28041977
Cancer Res. 2003 Jul 15;63(14):4112-8
pubmed: 12874015
Med Oncol. 2015 Jan;32(1):370
pubmed: 25428383
Nat Med. 2007 Feb;13(2):139-45
pubmed: 17290272
J Cell Physiol. 2018 Feb;233(2):774-786
pubmed: 28109133
Gene Ther. 2014 Apr;21(4):393-401
pubmed: 24572789
Int J Cancer. 2006 Mar 1;118(5):1194-204
pubmed: 16152611
Br J Cancer. 2009 Aug 18;101(4):589-97
pubmed: 19623181
Breast Cancer Res Treat. 2010 Jul;122(1):211-7
pubmed: 19967556
Hepatology. 2006 Jun;43(6):1284-94
pubmed: 16729333
Immunol Cell Biol. 1997 Jun;75(3):223-30
pubmed: 9243286
Adv Nutr. 2016 Mar 15;7(2):418-9
pubmed: 26980827
Breast Cancer Res Treat. 2001 Jan;65(2):125-34
pubmed: 11261828
Biochem Biophys Res Commun. 2006 Feb 24;340(4):1158-66
pubmed: 16403434
Haematologica. 2005 Feb;90(2):274-5
pubmed: 15710591
J Clin Pathol. 1993 Feb;46(2):189-90
pubmed: 8459046
J Natl Cancer Inst. 2014 May 15;106(5):
pubmed: 24832787
N Engl J Med. 2011 Jun 23;364(25):2381-91
pubmed: 21639806
Zhonghua Zhong Liu Za Zhi. 2016 Dec 23;38(12):881-885
pubmed: 27998462
Cancer Gene Ther. 2000 Feb;7(2):255-61
pubmed: 10770634
J Clin Invest. 2002 Feb;109(3):409-17
pubmed: 11828001
Trends Pharmacol Sci. 2012 Jan;33(1):35-41
pubmed: 22032984
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4935-9
pubmed: 8197160
Crit Rev Oncol Hematol. 2016 Jan;97:22-9
pubmed: 26563820
PLoS One. 2017 Apr 5;12(4):e0172786
pubmed: 28379958
Clin Cancer Res. 2003 Oct 15;9(13):4802-10
pubmed: 14581351
Blood. 2005 Oct 1;106(7):2302-10
pubmed: 15976182
Clin Cancer Res. 2008 Dec 1;14(23):7790-7
pubmed: 19047106
Ann Oncol. 2008 Mar;19(3):496-500
pubmed: 18187488
Expert Rev Mol Diagn. 2017 Feb;17(2):153-165
pubmed: 28032524
Haematologica. 2004 Dec;89(12):1459-67
pubmed: 15590396
Blood. 2014 May 15;123(20):3116-27
pubmed: 24700781
DNA Cell Biol. 2004 Sep;23(9):549-60
pubmed: 15383175
Blood. 2000 Jan 15;95(2):610-8
pubmed: 10627470
Indian J Pathol Microbiol. 2013 Apr-Jun;56(2):89-93
pubmed: 24056641
Leukemia. 2004 Feb;18(2):189-218
pubmed: 14737178
Annu Rev Immunol. 2000;18:767-811
pubmed: 10837075
Br J Cancer. 2013 May 28;108(10):2063-9
pubmed: 23591198
Nat Immun Cell Growth Regul. 1991;10(5):278-88
pubmed: 1758468
Cancer Res. 1998 Apr 15;58(8):1695-9
pubmed: 9563485
BMC Cancer. 2013 Jul 26;13:361
pubmed: 23890049
J Cancer Metastasis Treat. 2015 Jul;1(2):94-100
pubmed: 28090590
Annu Rev Immunol. 1999;17:19-49
pubmed: 10358752